Innoviva (INVA) is back in focus after recent share price moves drew attention to its valuation and fundamentals. The stock closed at $21.17, with returns mixed over the past month and over the past three months.
Over the shorter term, Innoviva's share price has seen mild pressure, with the 30 day share price return down 1.26% and the 90 day share price return down 4.34%. At the same time, the year to date share price return of 6.54% and the 3 year total shareholder return of 61.11% point to momentum that has been built over a longer horizon despite the recent cooling.
Compare Innoviva's recent momentum with a hand picked group of companies by scanning the 49 high quality undervalued stocks that may also warrant a closer look.
For Innoviva, the recent pullback sits awkwardly beside its longer term gains and royalty heavy business. Are you seeing a temporary swing in sentiment or a reset that better matches the underlying valuation setup ahead?
Preferred Price-to-Earnings of 4.3x: Is it justified?
On Simply Wall St metrics, Innoviva looks inexpensive at a P/E of 4.3x compared to both its own fair value P/E estimate and the wider pharmaceuticals group. That low multiple sits alongside a $21.17 share price and a business with a royalty focused income stream and commercialised products.
The P/E ratio compares a company’s share price with its earnings per share. For a profitable biopharmaceutical company like Innoviva, it gives a quick sense of how much investors are currently paying for each dollar of earnings. A lower P/E can point to the market assigning a cautious or discounted view of those earnings, particularly when other indicators suggest higher valuation levels could be supported.
For Innoviva, the P/E of 4.3x is below the estimated fair P/E of 9.7x, below the US pharmaceuticals industry average of 16.8x and below the peer group average of 20.7x. That is a wide gap. If the fair ratio estimate proves more reflective of the company’s long run earnings power, market pricing could eventually shift closer to that level rather than where it currently trades. Result: Price-to-Earnings of 4.3x (UNDERVALUED)
To see how this valuation gap is calculated and how the fair ratio is derived for Innoviva, review the Explore the SWS fair ratio for Innoviva.
However, you also need to weigh Innoviva's reliance on royalty income and the recent decline in annual net income growth, which could challenge the current valuation story.
Find out about the key risks to this Innoviva narrative.
Another View on Innoviva using the SWS DCF model
While the low 4.3x P/E points to Innoviva looking inexpensive, the SWS DCF model paints an even starker picture. It suggests a fair value of $55.33 per share compared with the current $21.17 price, which implies the stock trades at a large discount under that framework.
The two methods raise different questions for you as an investor. Is the low P/E signaling caution about future earnings, or is the DCF pointing to an overreaction that has pushed Innoviva too far below its estimated cash flow value?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innoviva for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment on Innoviva split between opportunity and caution, consider reviewing the full picture promptly so you can decide where you stand on the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Innoviva?
If Innoviva has your attention, do not stop here. Broaden your watchlist with focused stock ideas that match different risk levels, income needs and balance sheet profiles.
- Target higher income potential by reviewing companies that feature 12 dividend fortresses for investors who care about consistent cash returns.
- Hunt for potential mispricing opportunities with the 18 high quality undiscovered gems that combine strong fundamentals with lower visibility.
- Prioritise resilience by scanning a list of solid balance sheet and fundamentals (51 results) so you are not caught off guard when conditions get tougher.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com